{"entity":{"id":"nct07385703","kind":"trial","name":"Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma","aka":[],"tldr":"A phase 3 trial testing LM-302 in gastric & gastro-oesophageal junction cancer, now recruiting.","summary":"Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma is a phase 3 interventional study registered as NCT07385703, led by Shanghai Chia Tai Tianqing Pharmaceutical Technology Development, and recruiting on the registry. Official title: A Randomised, Open-Label, Multicenter Phase III Study of Tecotabart Vedotin Plus Tislelizumab Versus Tislelizumab Plus Chemotherapy as First-Line Treatment in Patients With CLDN18.2-Positive, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma. Planned enrolment is 752 participants (estimated). The study started in 2026-04-15 and primary completion is expected in 2028-10. No results have been posted on ClinicalTrials.gov.","status":"recruiting","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov NCT07385703","url":"https://clinicaltrials.gov/study/NCT07385703"}],"tags":["ctgov-ingest"],"related":[],"cancers":["gastric","gastric-cldn18-2-positive"],"sections":[],"technologies":[],"targets":[],"drugs":["lm-302"],"companies":["sino-biopharm"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07385703","phase":"3","setting":"A Randomized, Open-Label, Multicenter Phase III Study of Tecotabart Vedotin Plus Tislelizumab Versus Tislelizumab Plus Chemotherapy as First-Line Treatment in Patients With CLDN18.2-Positive, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma","sponsor":"Shanghai Chia Tai Tianqing Pharmaceutical Technology Development","started":"2026-04-15","startedType":"actual","enrolled":752,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07385703/","neighbours":{"cancer":[{"id":"gastric-cldn18-2-positive","kind":"cancer","name":"Claudin 18.2-positive gastric cancer","route":"/cancers/gastric-cldn18-2-positive/"},{"id":"gastric","kind":"cancer","name":"Gastric & gastro-oesophageal junction cancer","route":"/cancers/gastric/"}],"drug":[{"id":"lm-302","kind":"drug","name":"LM-302","route":"/drugs/lm-302/"}],"company":[{"id":"sino-biopharm","kind":"company","name":"Sino Biopharmaceutical (Chia Tai Tianqing)","route":"/companies/sino-biopharm/"}]}}